The role of lipase maturation factor 1 in hypertriglyceridaemia and atherosclerosis: An update.

IF 2.3 Q2 MEDICINE, GENERAL & INTERNAL

SAGE Open Medicine Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI:10.1177/20503121241289828

Siarhei A Dabravolski, Alexey V Churov, Vasily N Sukhorukov, Tatiana I Kovyanova, Dmitry F Beloyartsev, Irina N Lyapina, Alexander N Orekhov

{"title":"The role of lipase maturation factor 1 in hypertriglyceridaemia and atherosclerosis: An update.","authors":"Siarhei A Dabravolski, Alexey V Churov, Vasily N Sukhorukov, Tatiana I Kovyanova, Dmitry F Beloyartsev, Irina N Lyapina, Alexander N Orekhov","doi":"10.1177/20503121241289828","DOIUrl":null,"url":null,"abstract":"<p><p>Lipase maturation factor 1 is an endoplasmic reticulum-resident transmembrane protein, which acts as a critical chaperone necessary for the folding, dimerisation, and secretion of lipases. In this review, we summarise data about the recently revealed role of lipase maturation factor 1 in endoplasmic reticulum redox homeostasis, its novel interaction partners among oxidoreductases and lectin chaperones, and the identification of fibronectin and the low-density lipoprotein receptor as novel non-lipase client proteins of lipase maturation factor 1. Additionally, the role of lipase maturation factor 1-derived circular RNA in atherosclerosis progression via the miR-125a-3p/vascular endothelial growth factor A\\Fibroblast Growth Factor 1 axis is discussed. Finally, we focus on the causative role of lipase maturation factor 1 variants in the development of hypertriglyceridaemia - a type of dyslipidaemia that significantly contributes to the development of atherosclerosis and other cardiovascular diseases via different mechanisms.</p>","PeriodicalId":21398,"journal":{"name":"SAGE Open Medicine","volume":"12 ","pages":"20503121241289828"},"PeriodicalIF":2.3000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526315/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SAGE Open Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20503121241289828","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Lipase maturation factor 1 is an endoplasmic reticulum-resident transmembrane protein, which acts as a critical chaperone necessary for the folding, dimerisation, and secretion of lipases. In this review, we summarise data about the recently revealed role of lipase maturation factor 1 in endoplasmic reticulum redox homeostasis, its novel interaction partners among oxidoreductases and lectin chaperones, and the identification of fibronectin and the low-density lipoprotein receptor as novel non-lipase client proteins of lipase maturation factor 1. Additionally, the role of lipase maturation factor 1-derived circular RNA in atherosclerosis progression via the miR-125a-3p/vascular endothelial growth factor A\Fibroblast Growth Factor 1 axis is discussed. Finally, we focus on the causative role of lipase maturation factor 1 variants in the development of hypertriglyceridaemia - a type of dyslipidaemia that significantly contributes to the development of atherosclerosis and other cardiovascular diseases via different mechanisms.

查看原文本刊更多论文

脂肪酶成熟因子 1 在高甘油三酯血症和动脉粥样硬化中的作用：最新进展。

脂肪酶成熟因子 1 是一种常驻内质网的跨膜蛋白，它是脂肪酶折叠、二聚化和分泌所必需的关键伴侣蛋白。在这篇综述中，我们总结了最近揭示的脂肪酶成熟因子 1 在内质网氧化还原平衡中的作用、它在氧化还原酶和凝集素伴侣之间的新型相互作用伙伴，以及纤维连接蛋白和低密度脂蛋白受体作为脂肪酶成熟因子 1 的新型非脂肪酶客户蛋白的鉴定数据。此外，我们还讨论了脂肪酶成熟因子 1 衍生的环状 RNA 通过 miR-125a-3p/ 血管内皮生长因子 A\ 成纤维细胞生长因子 1 轴在动脉粥样硬化进展中的作用。最后，我们重点讨论了脂肪酶成熟因子 1 变体在高甘油三酯血症发展过程中的致病作用--高甘油三酯血症是一种血脂异常，通过不同的机制极大地促进了动脉粥样硬化和其他心血管疾病的发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

SAGE Open Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

3.50

自引率

4.30%

发文量

289

审稿时长

12 weeks